2016;7:75130 –44. 37. Herron J, Smith N, Stanbery L, Aaron P, Manning L, Bognar E, et al. Vigil: personalized immunotherapy generating systemic cytotoxic T cell response. Cancer Sci Res. 2020;3:1 –4. 38. Tondini E, Arakelian T, Oosterhuis K, Camps M, van Duikeren S, Han W, et al. A poly-neoantigen DNA vaccine synergizes withPD-1 blockade to induce T cell-mediated tumor control. Oncoimmunology. 2018;8:1652539. https://doi.org/10.1080/ 2162402X.2019.1652539 . 39. Martin CJ, Datta A, Little ﬁeld C, Kalra A, Chapron C, Wawersik S, et al. Selective inhibition of TGF β1 activation overcomes pri- mary resistance to checkpoint blockade therapy by altering tumorimmune landscape. Sci Transl Med. 2020;12:eaay8456. 40. O ’Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71 –81. 41. Schumacher TN, Schreiber RD. Neoantigens in cancer immu- notherapy. Science. 2015;348:69 –74. 42. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD-1 blockade expands intratumoral memory T cells.Cancer Immunol Res. 2016;4:194 –203.